Kritische 8-K Meldungen
Stammdaten
Unternehmen
| Name | Roivant Sciences Ltd. |
|---|---|
| Ticker | ROIV |
| CIK | 0001635088 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Roivant Sciences Ltd. |
Status
| Zuletzt geprüft | 2026-03-28 04:37:40.365945 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | Epperly Melissa B, | Director | Open Market Sale | -41,861 | 28.68 | -1,200,573.48 | -7,8% | |
| 2026-03-16 | Epperly Melissa B, | Director | Open Market Sale | -41,861 | 28.68 | -1,200,573.48 | -7,8% | |
| 2026-02-23 | Torti Frank | Officer, President and Vant Chair | Open Market Sale | -587,390 | 27.51 | -16,159,098.90 | -104,5% | |
| 2026-02-20 | Torti Frank | Officer, President and Vant Chair | Open Market Sale | -1,012,610 | 27.15 | -27,492,361.50 | -177,8% | |
| 2026-02-19 | Torti Frank | Officer, President and Vant Chair | Open Market Sale | -1,400,000 | 27.42 | -38,388,000.00 | -248,2% | |
| 2026-02-13 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200,000 | 26.49 | -5,298,000.00 | -34,3% | |
| 2026-02-13 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200,000 | 26.49 | -5,298,000.00 | -34,3% | |
| 2026-02-09 | Sukhatme Mayukh | Director, Officer, President & CIO | Open Market Sale | -339,441 | 26.47 | -8,985,003.27 | -58,1% | |
| 2026-02-09 | Sukhatme Mayukh | Director, Officer, President & CIO | Open Market Sale | -339,441 | 26.47 | -8,985,003.27 | -58,1% | |
| 2025-12-15 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -353,745 | 22.05 | -7,800,077.25 | -50,4% | |
| 2025-12-15 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -353,745 | 22.05 | -7,800,077.25 | -50,4% | |
| 2025-12-12 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -1,975,858 | 21.96 | -43,389,841.68 | -280,6% | |
| 2025-12-12 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -1,975,858 | 21.96 | -43,389,841.68 | -280,6% | |
| 2025-12-11 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -774,142 | 21.64 | -16,752,432.88 | -108,3% | |
| 2025-12-11 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -774,142 | 21.64 | -16,752,432.88 | -108,3% | |
| 2025-11-17 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -539,650 | 20.51 | -11,068,221.50 | -71,6% | |
| 2025-11-17 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -539,650 | 20.51 | -11,068,221.50 | -71,6% | |
| 2025-11-14 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -1,027,670 | 20.33 | -20,892,531.10 | -135,1% | |
| 2025-11-14 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -1,027,670 | 20.33 | -20,892,531.10 | -135,1% | |
| 2025-11-13 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -287,283 | 20.81 | -5,978,359.23 | -38,7% | |
| 2025-11-13 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -287,283 | 20.81 | -5,978,359.23 | -38,7% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.